Thymosin alpha1: a historical overview.
Garaci. Enrico E
Key Findings
- Tα1 raises MHC‑I and Toll‑like receptor levels and stimulates cytokine production, indicating strong immune‑regulating effects.
- Combining Tα1 with cytokines or chemotherapy has been shown to slow tumor growth and improve infection control in immunocompromised subjects.
- Pilot clinical trials suggest potential benefits of Tα1 in hepatitis C and cancer patients.
Practical Outcomes
- For biohackers, Tα1 may be a useful immune‑support supplement, particularly for those with weakened immunity, but current data are preliminary. Until more detailed dosing studies emerge, it should be used cautiously and preferably under medical guidance.
Summary
Thymosin alpha‑1 is a peptide that can boost the immune system by increasing important immune markers and helping the body fight infections and tumors, especially when used with other immune‑boosting drugs. Early human trials in hepatitis C and cancer look promising, but exact dosing and protocols aren’t settled yet.
Abstract
Thymosin alpha 1 (Talpha1), initially isolated from thymus, was characterized by Allan Goldstein in 1977. Since the beginning, our studies were aimed at evaluating its immunomodulating effects when used in combination with cytokines and chemotherapy. Combination therapies have now proved to be effective in inhibiting tumoral growth and in controlling infective diseases especially in the immunocompromised host. More recent studies showed that Talpha1 molecule increased major histocompatibility complex (MHC) class-1 and Toll-like receptor expression as well as cytokine production, suggesting its immunoregulatory role. Overall these results led us to start pilot clinical trials on patients with hepatitis C and cancer.
Study Information
pubmed
2007
2007-06-13T00:00:00.000Z
10.1196/annals.1415.039
31
22